Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Glufast: Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Glufast - General Information

Glufast is a drug for the treatment of type 2 diabetes .Glufast is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

 

Pharmacology of Glufast

Glufast belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.

 

Additional information about Glufast

Glufast Indication: For the treatment of type 2 diabetes. Mechanism Of Action: Glufast is a novel antidiabetic agent for the treatment of type-2 diabetes mellitus. Its chemical structure is similar to that of sulphonylureas. Glufast exerts a hypoglycaemic effect with rapid onset and short duration of action, by transiently increasing insulin secretion. Glufast is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Glufast may also activate ryanodine receptors. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Mitiglinide Synonyms: Mitiglinide calcium hydrate Drug Category: Hypoglycemic Agents Drug Type: Small Molecule; Approved Other Brand Names containing Mitiglinide: Glufast; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Glufast: Not Available Chemical IUPAC Name: 4-(1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl)-4-oxo-2-(phenylmethyl)butanoic acid Chemical Formula: C19H25NO3 Mitiglinide on Wikipedia: https://en.wikipedia.org/wiki/Mitiglinide Organisms Affected: Not Available